Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known target in depression. Since its initial approval in 2019, Spravato has ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.